


4 Pharmaceutical Technology JANUARY 1993



PHARMACEUTICAL **TECHNOLOGY®**

Published monthly by ASTER PUBLISHING CORPORATION

Associate Editor Amy Vickland Senior Assistant Editor Patti Turner Assistant Editor Paul R. Wade Washington Editor Jill Wechsler Publications Art Director Barbara A. Mickelson Associate Art Director Marlene W. Marshall Associate Production Director Helen Hornick Advertising Coordinator Joan Hedgpeth

Group Publisher Brian Langille Group Editor Stefan Schuber

EDITORIAL OFFICES 859 Willamette Street (503) 343-1200 P.O. Box 10460 Telex: 510-597-0365 Eugene, Oregon 97440-2460 Fax: (503) 344-3514

SALES OFFICES

Director of Sales Paul Milazzo Director of Advertising Gary Durr National Sales Representative Margaret Papa Metuchen, New Jersey 08840 Fax: (908) 549-8927

Associate Publisher Ralph Vitaro 195 Main Street (908) 549-3000

ASTER PUBLISHING CORPORATION

Chief Executive Officer Edward D. Aster, Senior Vice-President Michael Aster, General Manager Mildred V. Burke, Editorial Director Steve Netherby, Production Director Stephen Roberts, Circulation Director Rick Wilkes, Conference Director Steve McNeil, Director of Market Research Robert T. Wolf, Marketing Services Director L. Ghio Imburgio.

MANUSCRIPTS: All submissions will be handled with reasonable care, but publishers assume no responsibility for safety of artwork, photographs, or manuscripts. Every precaution is taken to ensure accuracy, but publishers cannot accept responsibility for the accuracy of information supplied herein or for any opinion expressed.

SUBSCRIPTIONS: U.S. and possessions - 1 year (12 issues), \$59; 2 years (24 issues), \$108; 3 years (36 issues), \$156. Outside the U.S. - 1 year (12 issues), \$117; 2 years (24 issues), \$25; 3 years (36 issues), \$328. Delivery of *Pharmaceutical Technology* outside the United States is 3-14 days after printing. Single copy price – U.S., \$10 plus postage; outside the U.S., \$12 plus postage. For subscription information, write *Pharmaceutical Technology*, P.O. Box 7674, Riverton, NJ 08077-7674, USA; or call Toll-Free 1-800-949-6525. Outside of the United States, call (503) 343-1200, ext. 114.

CHANGE OF ADDRESS: Notices should be sent promptly; provide old mailing label as well as new address; include ZIP or postal code. Allow 4 to 6 weeks for change. **POSTMASTER**: Send address changes to Pharmaceutical Technology, P.O. Box 7674, Riverton, NJ 08077-7674, USA. Subscription Service Center: 1-800-949-6525.

REPRINTS: Reprints of all articles in this issue and past issues of this publication are available (250 minimum). Call or write: Mary Clark, Aster Marketing Services, 859 Willamette Street, P.O. Box 10460, Eugene, OR 97440-2460, USA, (503) 343-1200; Fax: (503) 686-5731.

CLASSIFIED DIRECTORY SALES: Contact Randy Yost, Aster Marketing Services, (503) 343-1200; Fax: (503) 686-5731

DIRECT MAIL LIST: Contact Randy Yost, Aster Marketing Services, (503) 343-1200; Fax: (503) 686-5731

RECRUITMENT ADVERTISING: Contact Dorothy Schick, Career Development Programs, Aster Marketing Services, (503) 343-1200; Fax: (503) 686-5731.

WBPA ABP


Second class postage paid at Eugene, Oregon, and at additional mailing offices.

©1992 by Aster Publishing Corporation. All rights reserved. Reproduction in part or whole without written permission is strictly prohibited. Authorization to photocopy items for internal or personal use is granted by Aster Publishing Corporation, provided that the base fee of \$1.00 per copy, plus \$.50 per page, is paid directly to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970. Pharmaceutical Technology (ISSN 0147-8087) and the logo appearing on the cover of this magazine are registered trademarks of Aster Publishing Corporation

A Survey of Current Industrial Practices in the Formulation and Manufacture of Tablets and Capsules

Ralph F. Shangraw* and Dudley A. Demarest Jr.

DOCKET



Dramatic changes in the formulation and manufacture of pharmaceutical dosage forms have occurred during the 15 years of *Pharmaceutical Technology*'s existence. Many of these changes have been motivated by the introduction of new processing equipment and new pharmaceutical excipients. Although marketing surveys by equipment and excipient suppliers have been conducted, most of the results are unpublished. In order to obtain a better understanding of industry attitudes toward both excipients and manufacturing processes, the authors designed a questionnaire to assess current industrial practices. The results of our survey are described in this article.

Ralph F. Shangraw, PhD, and Dudley A. Demarest Jr., PhD, are professors at the University of Maryland, School of Pharmacy, Baltimore, MD 21201, USA. Dr. Shangraw is a member of the Pharmaceutical Technology Editorial Advisory Board.

*To whom all correspondence should be addressed.

uestionnaires were mailed to one person at each of 68 different companies. Although an attempt was made to identify a person who would most likely be able to complete the questionnaire, addressees were asked to forward it to a more appropriate person if necessary. Questions were generally posed in the context of what recipients or. their companies were doing at present, thus attempting to determine current attitudes of formulators rather than what had been done in the past. A total of 58 questionnaires were returned, representing 30 innovator pharmaceutical companies, 14 generic companies, 8 nonprescription drug companies, and 6 vitamin and nutritional supplement companies.

The questionnaire was divided into several sections. The first two sections asked formulators about their use of excipients in tablets and capsules. The last two sections inquired about their companies' current formulation policies and general excipient use.

No matter where your pharmaceuticals travel Klöckner rigid films provide the perfect packaging climate.

Packaging pharmaceuticals for today's expanding markets can be a major headache. Geography, humidity and changing climatic conditions all pose a serious challenge to product integrity and efficacy.

To meet that challenge, Klöckner is the only U.S. manufacturer of vinyl or polyester thermoform films that meet or surpass all international barrier property standards. Klöckner rigid films give you better MVTR properties (virtually 15% better than comparable U.S. made films); better shelf life; better product protection. Pentapharm[®] Rigid Films—High performance mono-films with better barrier qualities. You save testing time for NDA's. Ideal for 70% to 80% of your blister requirements.

Pentapharm Alfoil P—Rigid film with customized PVDC coating for increased hygroscopic protection.

Pentapharm Alfoil T—Multi-layer (PVC/PE/PVDC) high barrier protection for products that are extremely moisture and gas sensitive. No matter how far your products travel, we can provide the packaging films you need to take them there. The formulations, thicknesses and combinations you want. So let it rain in Rio or stay dry in Tucson—we've got you covered.

Discover the unsurpassed quality and superior barrier protection of Klöckner rigid films. Call (703) 832-3600. Klöckner Pentaplast, Gordonsville, Virginia 22942.

LOCKNER

PENTAPLAST

Rigid film, machinery and service. Worldwide.


Circle 26



DOCKE.

Pentapharm Customized Films-

Klöckner R&D will develop customdesigned films — in a full range of formulations and thicknesses — to meet any specific product or market requirement.



TABLETS

The first question asked respondents to rank filler binders in terms of first, second, third, etc., choices. The results in Figure 1 show that lactose and microcrystalline cellulose were preferred. The reasons for this preference are shown in Table I. Lactose was chosen because of its solubility and compatibility and microcrystalline cellulose because of its compactibility, compatibility, and uniformity of supply. In contrast, dicalcium phosphate was chosen mainly because of compatibility with no perceived benefit from solubility.

The different types of filler binders preferred are shown in Figures 2a-c. Modified lactose (alpha monohydrate) was preferred over other types of lactose, which may indicate a preference for its utility in direct compression. Those using starch preferred the pregelatinized form. For calcium phosphate, the preference (in descending order) was




Figure 1: Preference for tablet fillerbinders (58 responses).

Table I: Reasons for preferences of filler-binders.

Reasons	Lactose	Starch	Microcrystalline Cellulose	Calcium Phosphate
Solubility	.19	4	9	1
Cost	15	6	. 3	2
Tradition	21	9	18	4
Compatibility	20	7	33	3
Uniformity of supply	14	4	26	3
Compactibility	17	6	46	8
Handling	8	3	11	0
Physiological inertness	8	1	16	2
Total selections	41	12	52	8

Table II: Reasons for preferences of disintegrating agents.

DOCKE

		Sodium Starch		*
Reason	Starch	Glycolate	Croscarmellose	Crospovidone
Disintegration/				
dissolution	11	27	40	17
Cost	9	2	0	1
Tradition	12	16	8	3
Compatibility	6	12	12	7
Uniformity of supply	3	13	23	· 8
		Cond	entrations	
Common	10%	5%	2%	
Range	5-20	0.5-15	0.5-8	0.5-4
Total selections	20	34	44	18




Figure 2: (a) Filler-binder preference: (a) lactose (55 responses), (b) starch (56 responses), (c) calcium phosphate (49 responses).

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.